Article ; Online: Oncologic Safety of One-Stage Implant-Based Breast Reconstruction in Breast Cancer Patients With Positive Sentinel Lymph Nodes: A Single-Center Retrospective Study Using Propensity Score Matching.
2023 Volume 24, Issue 1, Page(s) e1–e8
Abstract: Objective: The purpose of this study is to evaluate the oncologic safety of one-stage implant-based breast reconstruction (OIBR) following mastectomy in breast cancer patients with positive sentinel lymph nodes (SLNs).: Methods: We collected clinical ...
Abstract | Objective: The purpose of this study is to evaluate the oncologic safety of one-stage implant-based breast reconstruction (OIBR) following mastectomy in breast cancer patients with positive sentinel lymph nodes (SLNs). Methods: We collected clinical and pathological data from breast cancer patients with positive SLNs who underwent OIBR or not after mastectomy between January 2015 and December 2018. A total of 194 patients were included, with 130 patients undergoing mastectomy alone (MA) and 64 patients receiving OIBR after mastectomy. The clinical and pathological features, as well as the postoperative oncologic outcomes, of the 2 groups were retrospectively analyzed. Propensity score matching (PSM) was employed to mitigate the effects of data bias and confounding factors. Results: The median follow-up time was 66 months for the OIBR group and 64 months for the MA group after PSM. The majority of reconstructive surgeries use an approach of prosthetic implantation (52.0%). This is followed by prosthetic implantation combined with a latissimus dorsi (LD) flap (32.0%), and acellular dermal matrix (ADM)-assisted implant placement (16.0%). During the follow-up period, a local recurrence was observed in 1 case, regional recurrence in 3 cases, and distant metastasis leading to death in 3 cases among the OIBR group patients. No significant difference was found between the OIBR and MA groups in disease-free survival (DFS) (P = .66), distant metastasis-free survival (DMFS) (P = .91), locoregional recurrence-free survival (LRRFS) (P = .44), and overall survival (OS) (P = .57). Conclusion: OIBR is a safe option for breast cancer patients with positive SLNs and does not negatively impact cancer recurrence or overall survival. |
---|---|
MeSH term(s) | Humans ; Female ; Breast Neoplasms/pathology ; Mastectomy ; Retrospective Studies ; Sentinel Lymph Node/surgery ; Sentinel Lymph Node/pathology ; Propensity Score ; Neoplasm Recurrence, Local/pathology ; Mammaplasty ; Lymph Nodes/surgery ; Lymph Nodes/pathology |
Language | English |
Publishing date | 2023-09-13 |
Publishing country | United States |
Document type | Journal Article |
ZDB-ID | 2106734-X |
ISSN | 1938-0666 ; 1526-8209 |
ISSN (online) | 1938-0666 |
ISSN | 1526-8209 |
DOI | 10.1016/j.clbc.2023.09.007 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 5800: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG) |
|||
Zs.MO 498: Show issues |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.